When did NewAmsterdam Pharma (NAMS) last report earnings?

NewAmsterdam Pharma last reported on Aug 6, 2025, covering fiscal Q2 2025.

Did NAMS beat earnings estimates?

Yes. NewAmsterdam Pharma reported EPS of −$0.15 for Q2 2025 against a −$0.46 estimate — a 67.62% beat.

How much revenue did NAMS report last quarter?

NewAmsterdam Pharma reported $19.1M in revenue for Q2 2025, against a consensus estimate of $3.5M.

NewAmsterdam Pharma (NAMS) earnings history

Most recent quarter

Fiscal period: Q2 2025
Period end: Jun 30, 2025
EPS actual: −$0.15
EPS estimate: −$0.46
EPS surprise: +67.62%
Revenue surprise: +447.99%
Revenue: $19.1M
Revenue estimate: $3.5M
Reported: Aug 6, 2025
SEC filing: View filing

Earnings history

Period	Reported	EPS estimate	EPS actual	Surprise	Revenue	Filing
Q2 2025	Aug 6, 2025	−$0.46	−$0.15	+67.62%	$19.1M	SEC
Q1 2025	May 8, 2025	−$0.49	−$0.35	+29.88%	$3.0M	SEC
Q4 2024	Feb 26, 2025	−$0.49	−$0.93	−91.28%	$12.8M	SEC
Q2 2024	Aug 7, 2024	−$0.58	−$0.41	+28.92%	$2.3M	SEC

Quarterly revenue

Q2 2024

$2.3M

Q4 2024

$12.8M

Q1 2025

$3.0M

Q2 2025

$19.1M

Frequently asked questions

When did NewAmsterdam Pharma (NAMS) last report earnings?
NewAmsterdam Pharma last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did NAMS beat earnings estimates?
Yes. NewAmsterdam Pharma reported EPS of −$0.15 for Q2 2025 against a −$0.46 estimate — a 67.62% beat.
How much revenue did NAMS report last quarter?
NewAmsterdam Pharma reported $19.1M in revenue for Q2 2025, against a consensus estimate of $3.5M.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by